Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

22nd May 2017 (Last Updated May 22nd, 2017 04:32)

GlobalData captured records of 1,825 clinical trials across all diseases and phases that had a start date between 2012 and 2016 with at least one clinical site location in Russia.

Type 2 Diabetes Leads Indications in Russian Clinical Trials, 2012-2016

As part of GlobalData's series of white papers tracking clinical trials activity in emerging markets, the company covered Russia in January 2017.

GlobalData captured records of 1,825 clinical trials across all diseases and phases, which had a start date between 2012 and 2016 with at least one clinical site location in Russia.

Among all the indications for clinical trials in this dataset, the largest number of trials was carried out for type 2 diabetes, followed by rheumatoid arthritis, non-small cell lung cancer, asthma, and breast cancer. Based on the phase-wise distribution of clinical trials for the five major indications, Phase III trials were predominant. Type 2 diabetes was the indication with the most Phase III trials and the least number of Phase II trials as compared to other top five indications (see Figure 1).

Diabetes

Source: GlobalData, Pharma Intelligence Center, Clinical Trials Database [Accessed May 18, 2017]